725P - Treatment of patients with metastatic or relapsed cervical cancer: Results from a quality assurance program of the AGO Study Group

Background

Real-world data on treatment patterns and outcomes in recurrent or metastatic cervical cancer (r/mCC) are lacking. Hence, understanding treatment patterns and their respective outcome is imperative to design future clinical trials and develop appropriate treatment algorithms.

Methods

Within this retrospective analysis patients with r/mCC diagnosed between 2018 and 2022 were identified from medical records of 31 gynecologic cancer centers in Germany. Patient demographic and clinical characteristics, treatment patterns, and clinical outcomes were assessed descriptively. Progression-free- (PFS) and overall survival (OS) was calculated using Kaplan-Meier analysis.

Results

A total of 503 eligible patients (median age 55 years; IQR 45-63) were analyzed. Thereof 217 (43%) had primary disseminated metastatic disease, and 286 (57%) had recurrent disease, and received systemic treatment for r/mCC. 276/503 patients (55%) received first line (1L) chemotherapy (platinum combination: 247/276; 79%) followed by targeted maintenance therapy with Bevacizumab (177/247; 72%), immunotherapy (19/247; 8%), or both combined (50/247; 20%). 111/503 (22%) received chemotherapy only (platinum combination: 64/111; 58%, platinum mono: 35/111; 31%, or platinum-free: 12/111; 11%), and 110/503 (22%) did not receive any systemic treatment. For these subgroups after a median follow-up of 16 months, the PFS was 12 months (95%-CI 11-14), 8.8 months (95%-CI 7.1-11), and 3 months (95%-CI 2.3-4.8), and OS was 25 months (95%-CI 21-31), 17 months (95%-CI 14-22), and 3.6 months (95%-CI 2.8-5.3), respectively. 176/283 (62%) patients who developed progressive disease (PD) were treated with second line (2L) therapy: platinum-based chemotherapy and maintenance (37/176; 21%); chemotherapy only (65/176; 37%), immunotherapy (59/176; 33%); Antibody-Drug-Conjugate (15/176; 9%).

Conclusions

Only half of the patients with r/mCC were treated 1L with platinum-combination therapy including maintenance. Moreover, 22% at initial diagnosis and 38% at PD were not treated with systemic therapy at all. This might reflect poor performance status, patients’ preference, and/or lack of effective therapies especially in 2L treatment.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

AGO Study Group.

Funding

AGO Research Study Group.

Disclosure

D. Denschlag: Financial Interests, Personal, Invited Speaker: AstraZeneca, GSK, MSD, KLS Martin, Intuitive; Financial Interests, Personal, Advisory Board: AstraZeneca, Eisai, GSK, KLS Martin, MSD, PharmaMar, Seagen. F. Heitz: Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, GSK, NovoCure; Financial Interests, Personal, Invited Speaker: AstraZeneca, GSK. M. Kerkmann: Financial Interests, Personal, Full or part-time Employment: MMF GmbH; Financial Interests, Institutional, Research Grant: AstraZeneca, Roche, Amgen, Bristol Myers Squibb, Janssen-Cilag, Pharmacosmos, MSD, Takeda; Non-Financial Interests, Member: Working Group Medical Oncology (AIO) of the German Cancer Society (DKG), Working Group Supportive Care (AGSMO) of the German Cancer Society (DKG), German Cancer Society (DKG). L. Woelber: Financial Interests, Personal, Advisory Board: GSK, Roche, MSD, Eisai, Seagen, AstraZeneca; Financial Interests, Personal, Invited Speaker: Pfizer, Roche, MSD, Seagen, AstraZeneca, Novartis; Financial Interests, Personal, Other, scientific board: Med Update GmbH; Financial Interests, Personal, Other, speaker: Med Publico GmbH; Financial Interests, Institutional, Coordinating PI: Seagen, Medac Oncology; Financial Interests, Institutional, Local PI: MSD, Vaccibody AS, Roche; Non-Financial Interests, Institutional, Product Samples: Roche diagnostics; Non-Financial Interests, Leadership Role, current president: ECSVD; Non-Financial Interests, Leadership Role: AGO study group, AGO commission vulva vagina. N. de Gregorio: Financial Interests, Personal, Advisory Board: AstraZeneca, Roche, Myriad, Novartis, MSD, GSK, Clovis, Gilead; Other, travel expenses: AstraZeneca, Gilead. P. Wimberger: Financial Interests, Personal and Institutional, Research Funding: Amgen, AstraZeneca, MSD, GSK, Novartis, Pfizer, Roche, Clovis, Lilly; Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, MSD, GSK, Novartis, Pfizer, Roche, Clovis, Teva, Eisai, Lilly, Gilead, Daichii Sankyo; Financial Interests, Personal, Invited Speaker: Amgen, AstraZeneca, MSD, GSK, Novartis, Pfizer, Roche, Clovis, TEVA, Eisai, Lilly, Gilead, Daichii Sankyo. S. Mittelstadt: Financial Interests, Personal, Sponsor/Funding: AstraZeneca. H. Bronger: Financial Interests, Personal, Invited Speaker: GSK, AstraZeneca. P. Harter: Financial Interests, Personal, Advisory Board, Value includes honoraria for lectures: AstraZeneca; Financial Interests, Personal, Advisory Board, includes honoraria for lectures: GSK, Roche, MSD; Financial Interests, Personal, Invited Speaker: Amgen, Stryker, Zailab, Eisai, Daiichi Sankyo; Financial Interests, Personal, Advisory Board: Clovis, ImmunoGen, Novartis, Mersana, Miltenyi, Exscientia; Financial Interests, Personal, Other, IDMC member: Sotio; Financial Interests, Institutional, Trial Chair: AstraZeneca, Roche, GSK, ImmunoGen; Financial Interests, Institutional, Local PI: Genmab; Financial Interests, Institutional, Funding: Seagen, Clovis; Financial Interests, Institutional, Other, Co-investigator: Novartis; Non-Financial Interests, Principal Investigator: AstraZeneca; Other, Travel support for conference: AstraZeneca. B. Czogalla: Financial Interests, Personal, Invited Speaker: AstraZeneca. All other authors have declared no conflicts of interest.